Nothing Special   »   [go: up one dir, main page]

IL152905A0 - Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease - Google Patents

Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease

Info

Publication number
IL152905A0
IL152905A0 IL15290502A IL15290502A IL152905A0 IL 152905 A0 IL152905 A0 IL 152905A0 IL 15290502 A IL15290502 A IL 15290502A IL 15290502 A IL15290502 A IL 15290502A IL 152905 A0 IL152905 A0 IL 152905A0
Authority
IL
Israel
Prior art keywords
implications
neuronal
induction
bone marrow
gene therapy
Prior art date
Application number
IL15290502A
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Priority to IL15290502A priority Critical patent/IL152905A0/en
Publication of IL152905A0 publication Critical patent/IL152905A0/en
Priority to JP2004553057A priority patent/JP2006506086A/en
Priority to AU2003302134A priority patent/AU2003302134A1/en
Priority to PCT/IL2003/000972 priority patent/WO2004046348A1/en
Priority to CA002506050A priority patent/CA2506050A1/en
Priority to EP03811473A priority patent/EP1563059A1/en
Priority to US11/130,197 priority patent/US20050265983A1/en
Priority to US13/783,607 priority patent/US20130236964A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15290502A 2002-11-17 2002-11-17 Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease IL152905A0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL15290502A IL152905A0 (en) 2002-11-17 2002-11-17 Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease
JP2004553057A JP2006506086A (en) 2002-11-17 2003-11-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
AU2003302134A AU2003302134A1 (en) 2002-11-17 2003-11-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
PCT/IL2003/000972 WO2004046348A1 (en) 2002-11-17 2003-11-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
CA002506050A CA2506050A1 (en) 2002-11-17 2003-11-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
EP03811473A EP1563059A1 (en) 2002-11-17 2003-11-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US11/130,197 US20050265983A1 (en) 2002-11-17 2005-05-17 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US13/783,607 US20130236964A1 (en) 2002-11-17 2013-03-04 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15290502A IL152905A0 (en) 2002-11-17 2002-11-17 Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease

Publications (1)

Publication Number Publication Date
IL152905A0 true IL152905A0 (en) 2003-06-24

Family

ID=30011929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15290502A IL152905A0 (en) 2002-11-17 2002-11-17 Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease

Country Status (6)

Country Link
EP (1) EP1563059A1 (en)
JP (1) JP2006506086A (en)
AU (1) AU2003302134A1 (en)
CA (1) CA2506050A1 (en)
IL (1) IL152905A0 (en)
WO (1) WO2004046348A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
WO2006090745A1 (en) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. Neurotization promoting agent
JP2008546385A (en) 2005-06-16 2008-12-25 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド Isolated cells and populations containing isolated cells for treating CNS disease
CA2649148C (en) 2006-04-13 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
EP2135946B1 (en) * 2007-03-15 2015-12-09 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
AU2008284753B2 (en) 2007-08-07 2014-01-16 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
RU2486245C2 (en) 2007-10-15 2013-06-27 Чугаи Сейяку Кабусики Кайся Method of producing cell capable to produce heteroproteins with high yield
BRPI0818764B1 (en) 2007-10-24 2017-11-21 Chugai Seiyaku Kabushiki Kaisha PROCESS OF PRODUCTION OF A POLYPEPTID
JP2009183204A (en) * 2008-02-06 2009-08-20 Nara Institute Of Science & Technology Cell culturing method
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
JP5715050B2 (en) 2009-04-22 2015-05-07 中外製薬株式会社 Method for producing cells producing high production of heterologous protein
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
CN103890163B (en) 2011-06-19 2016-09-14 阿博根公司 Device, solution and method for sample collecting
US9717761B2 (en) 2011-11-21 2017-08-01 Ramot At Tel-Aviv University Ltd. Stem cell-derived neural cells for cell therapy in neurological disorders
CA2877223C (en) 2012-08-06 2019-08-27 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
EP3058063B1 (en) 2013-10-14 2018-06-06 Hadasit Medical Research Services and Development Ltd. Method of obtaining terminally differentiated neuronal lineages
EP3105587B1 (en) 2014-02-11 2023-09-06 Brainstorm Cell Therapeutics Ltd. Method of qualifying cells
US12038434B2 (en) 2015-02-09 2024-07-16 DNA Genotek, Inc. Devices, solutions and methods for sample collection related applications, analysis and diagnosis
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US10961556B2 (en) 2016-08-15 2021-03-30 Danmarks Tekniske Universitet Method for reducing ammonium and lactate production in CHO cells
WO2018178987A1 (en) * 2017-03-30 2018-10-04 Ramot At Tel-Aviv University Ltd. Methods of treating alzheimer's disease
GB2587319A (en) * 2019-08-12 2021-03-31 Healing Genes Llc Genetic construct
CN118591400A (en) 2021-11-29 2024-09-03 拉莫特特拉维夫大学有限公司 Methods and compositions for treating spinal cord injury
WO2024116183A1 (en) 2022-11-29 2024-06-06 Matricelf Ltd. Methods for decellularizing human omentum and products generated therefrom

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926639T2 (en) * 1998-05-07 2006-06-08 University Of South Florida, Tampa BONE MARROW CELLS AS A SOURCE OF NEURONS FOR THE RECONSTRUCTION OF BRAIN AND BONE MARROW

Also Published As

Publication number Publication date
EP1563059A1 (en) 2005-08-17
JP2006506086A (en) 2006-02-23
AU2003302134A1 (en) 2004-06-15
CA2506050A1 (en) 2004-06-03
WO2004046348A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
IL152905A0 (en) Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease
AU2002331798A1 (en) Multi-lineage directed induction of bone marrow stromal cell differentiation
AU2003262628A8 (en) Bone marrow cell differentiation
AU2003215099A8 (en) Anterior spinal implant
AU2003220424A1 (en) Adipose stromal stem cells for tissue and vascular modification
AU2003285172A8 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
AU2003200703A1 (en) Methods for Governing Bone Growth
EP1631321A4 (en) Structural/biological implant system
HK1076739A1 (en) Use of urease for inhibiting cancer cell growth
AU2003220115A8 (en) Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
AU2003274972A8 (en) Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
AU2002337479A8 (en) Compositions comprising bone marrow cells, demineralized bone matrix and rtg polymers for use in the induction of bone and cartilage formation
AU2002952675A0 (en) Clinical assistant for cochlear implant care
DE60041340D1 (en) IDENTIFICATION OF PLASMODIUM FALCIPARUM ERYTHROZN TO CHONDROITIN SULFATE A MEDIATED
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
IL148936A0 (en) Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
AU2003261651A1 (en) Novel implantable artificial breast silicon shell
AU2003260095A8 (en) Methods for recruiting patients for clinical studies
AU2003276009A8 (en) Regulation of human 3', 5' cyclic nucleotide phosphodiesterase pde1c
AU2003301312A8 (en) Bone marrow cell differentiation
AU2003277205A1 (en) Adult bone marrow derived stem cells
EP1494702A4 (en) Composition for stimulating de novo bone induction
UA67666A (en) Method for treating parkinson's disease
GB0512638D0 (en) Polymorphisms in TH CLCN7 gene as genetic markers for bone mass
GB0221330D0 (en) Growth factor for cell culture